Channelchek’s Post

New Research Report: Ocugen (OCGN) – Progress In Clinical Trials Overshadows FY2023 Filing Delay $OCGN #Investing #EquityResearch #Biotechnology #GeneTherapy https://lnkd.in/e_C_aKhG

New Research Report: Ocugen (OCGN) – Ocugen Clinical Showcase Highlights Fundamentals, Clinical Data, and Patient Stories $OCGN #Investing #EquityResearch #Biotechnology #GeneTherapy https://lnkd.in/eGZWvE-x

Nice article by Chen K and colleagues recently published at #Nature #Biotechnology supporting that complexes consisting of a newly engineered, thermostable #Cas9, ribonucleoproteins (#RNPs) and lipid #nanoparticle (#LNP) can expand the #therapeutic potential of #genome #editing. https://lnkd.in/gxb7qBxG

During the transcription of mRNA, or after transcription, breakages can occur which are not directly detectable through Sanger sequencing. We utilize our proprietary Next Generation Sequencing (NGS) method, which can detect breakages above the level of 0.1%, and accurately assess the integrity of mRNA. This method is more precise compared to Capillary Electrophoresis (CE). This method is also extremely important for assessing the integrity of saRNA. #RNAtherapeutics #mRNA #VaccineDevelopment #GeneTherapy #cellandgenetherapy #carttherapy #celltherapy #CRISPR #GeneEditing #PrimeEditing #biotech #biotechnology #drugdiscovery #circrna #LNP

If you are attending #NBC2024 of AAPS, I will be discussing with the industry leaders in Cell & Gene Therapies about the current challenges and opportunities in the panel section hosted by Praveen Tyle, especially the market access and development in the rare disease space. Look forward to the discussion!

FSD Pharma has a remylenating drug called Lucid MS that can target all forms of MS. The idea exists that MS has a neurodegenerative component seperate from the auto immune aspect. Thus the need for remyelinating therapies for multiple sclerosis patients around the world. Any stakeholders that want more info reach out to me , including #investmentbanking community thanks.

At #MeetingOnTheMesa in Phoenix, Oct. 7-9, BioSpace will provide on-site coverage exploring the progress and stumbling blocks for the #CellAndGeneTherapy sector, including the #regulatory, #manufacturing and #commercialization challenges facing the industry. Here's a preview of some of the issues stakeholders will be discussing next week. https://lnkd.in/gqf7EZnK #CGMesa24 #celltherapy #genetherapy #celltherapies #genetherapies #biotech #biotechnology #regenerativemedicine

"Anti-Biofilm Activity of Cannabigerol (CBG) against Streptococcus mutans" Abstract Streptococcus mutans is a common cariogenic bacterium in the oral cavity involved in plaque formation. Previous studies showed that Cannabigerol (CBG) has bacteriostatic and bacteriocidic activity against S. mutans. The aim of the present study was to study its effect on S. mutans biofilm formation and dispersion. S. mutans was cultivated in the presence of CBG, and the resulting biofilms were examined by CV staining, MTT assay, qPCR, biofilm tracer, optical profilometry, and SEM. Gene expression was determined by real-time qPCR, extracellular polysaccharide (EPS) production was determined by Congo Red, and reactive oxygen species (ROS) were determined using DCFH-DA. CBG prevented the biofilm formation of S. mutans shown by reduced biofilm biomass, decreased biofilm thickness, less EPS production, reduced DNA content, diminished metabolic activity, and increased ROS levels. CBG altered the biofilm roughness profile, resulting in a smoother biofilm surface. When treating preformed biofilms, CBG reduced the metabolic activity of S. mutans with a transient effect on the biomass. CBG reduced the expression of various genes involved in essential metabolic pathways related to the cariogenic properties of S. mutans biofilms. Our data show that CBG has anti-biofilm activities against S. mutans and might be a potential drug for preventive treatment of dental caries." Study: https://lnkd.in/g2zhJpzk

Advanced therapy developers and researchers are doing their utmost to improve and accelerate the journey of their products from the bench to the bedside. The supporting transport, logistics, and storage specialists tasked with the preservation and delivery of those products are working just as hard to improve their own products and services – and keep pace with a rapidly developing modality. Cryopreservation is seen as a key technology for advanced therapy supply chains, but it’s a technique with many challenges. Here, three experts from the cryopreservation field discuss what is happening now, and what could happen in the future. https://lnkd.in/e7DMUrZK #Biobank #Biobanking #Biorepository #Cryopreservation #PersonalizedMedicines #Freezing #Theraputics #SupplyChain #Biotechnology #Cryogenics Stella K. Vnook | Priya Baraniak, Ph.D. | The Medicine Maker